LiDCO Group Plc Posting of Annual Report and Notice of AGM (2738M)
May 07 2020 - 11:00AM
UK Regulatory
TIDMLID
RNS Number : 2738M
LiDCO Group Plc
07 May 2020
LiDCO Group PLC
("LiDCO" or the "Company")
Posting of Annual Report and Notice of Annual General
Meeting
LiDCO (AIM: LID), the hemodynamic monitoring company, announces
that its Annual Report and Accounts for the year ended 31 January
2020 (the "Annual Report") and Notice of the Annual General Meeting
("Notice of AGM") are today being posted to all shareholders who
had requested paper copies of those documents. All other
shareholders will be sent the Notice of AGM and notification that
the Annual Report will be published on the Company's website at
www.lidco.com/investors.
No form of proxy has been posted to shareholders, instead
shareholders have been informed, in the documents sent today, that
they will be able to vote electronically using the website
www.signalshares.com or may request a paper proxy form directly
from the registrars.
AGM arrangements
The Company will hold its AGM on Monday 1 June 2020 at 10.00 am.
The Company considers the safety and wellbeing of both its
shareholders and employees to be of paramount importance and with
this in mind, the Company has made arrangements to comply with the
current measures regarding restrictions on travel, limited
gatherings and the 'stay at home' instructions introduced by the UK
Government.
Only the Chairman of the meeting and one other person will
attend the AGM thus fulfilling the requirement of the Company's
Articles of Association for a quorum to be present consisting of
two persons entitled to vote upon the business to be transacted
present in person or by proxy. Accordingly, other shareholders and
proxies for shareholders will not be permitted to attend the AGM
and shareholders are instead urged to submit electronic or paper
proxy votes. Details on submitting proxy votes are contained in the
Notice of AGM.
The results of voting on the resolutions at the AGM will be
announced shortly afterwards and made available on the Company's
website.
The Board will continue to monitor COVID-19 developments as well
as any further UK Government advice and will issue a further
statement if the above arrangements require any amendment.
LiDCO Group Plc www.lidco.com
Matt Sassone (CEO) Tel: +44 (0)20 7749
1500
Tim Hall (CFO)
N+1 Singer (Nominated adviser and broker) Tel: +44 (0)20 7496
3172
Aubrey Powell / George Tzimas (Corporate
Finance)
Tom Salvesen (Corporate Broking)
Walbrook PR Ltd Tel: +44 20 7933 8780 or lidco@walbrookpr.com
Paul McManus Mob: +44 7980 541
893
Lianne Cawthorne Mob: +44 7584 391
303
About LiDCO Group Plc ( www.lidco.com )
LiDCO is a supplier of non-invasive and minimally invasive
hemodynamic equipment to hospitals used to monitor the amount of
blood flowing around the body and ensure that vital organs are
adequately oxygenated. LiDCO's products facilitate the application
of hemodynamic optimisation protocols for high risk patients in
both critical care units and in the operating theatre.
Increasingly clinical studies have shown that the optimisation
of patients' hemodynamic status in high risk patients produces
better outcomes and reduced hospital stay. LiDCO's computer-based
technology, developed originally at St Thomas' Hospital in London,
has been shown to significantly reduce morbidity and complications,
length of stay and overall costs associated with major surgery.
In critical care, LiDCO's products have various in-built guided
clinical protocols such as an end expiratory occlusion test (EEOT)
and a tidal volume challenge (TVC), as a means to assess a
patient's fluid status. These methods have been referenced by key
opinion leaders as an important part of the treatment pathway for
ventilated patients with the Covid-19 coronavirus in critical
care.
Key Products:
LiDCOunity: a hemodynamic monitor that combines the full suite
of LiDCO technology (non-invasive, minimally invasive and
calibrated technologies) into one platform. Designed to have the
flexibility to adapt to a patient's changing acuity, the product
enables clinicians to seamlessly transition between non-invasive,
minimally invasive and calibrated hemodynamic monitoring.
LiDCOplus : a computer-based platform monitor used in the
Intensive Care Unit for real-time continuous display of hemodynamic
parameters including cardiac output, oxygen delivery and
fluid-volume responsiveness (PPV% and SVV%).
LiDCOrapid : a cardiac output monitor designed specifically for
use in the operating theatre for fluid and drug management. The
monitor enables anaesthetists to receive accurate and immediate
feedback on the patient's fluid and hemodynamic status - a key
measure of overall well-being before, during and after surgery. The
LiDCOrapid provides:
-- early and rapid warning of hemodynamic change to aid choice
of therapeutic route: fluid or drug
-- quantification of hemodynamic response guidance on effective
delivery of fluids to ensure the right amount at the right time
The software incorporated into LiDCOrapid allows the LiDCOrapid
monitor to co-display Medtronic's level of consciousness parameter
('BIS(TM') )* and add the convenience of CNSystem's continuous
non-invasive blood pressure monitoring ('CNAP')**. This addresses a
growing requirement for non-invasive monitoring solutions that are
more comprehensive and can effectively replace multiple single
parameter monitors.
LiDCOview : an easy-to-use graphical display of historical
LiDCOplus and LiDCOrapid hemodynamic data.
*BIS (TM) and Bispectral Index are trademarks of Medtronic
registered in the US and foreign countries.
**CNAP(TM) is a trademark of CNSystems Medizintechnik AG.
LiDCO monitors use single-patient disposables (sensors or
smartcards) which provide an ongoing revenue stream.
LiDCO Distribution Network :
LiDCO sells directly to hospitals in the UK and USA and through
a network of specialty critical care and anaesthesia distributors
in the rest of the world.
LiDCO's headquarters are in London and its shares are traded on
AIM.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCZZGGKLNNGGZG
(END) Dow Jones Newswires
May 07, 2020 11:00 ET (15:00 GMT)
Lidco (LSE:LID)
Historical Stock Chart
From Apr 2024 to May 2024
Lidco (LSE:LID)
Historical Stock Chart
From May 2023 to May 2024